Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of MRW, please enable cookies in your browser

We'll assume we have your consent to use cookies, so you won't need to log in each time you visit our site.
Learn more

GlaxoSmithKline to cut medicine production waste

Pharmaceutical giant GlaxoSmithKline has set a target to cut its drug production waste by two thirds by 2015, according to the Financial Times.

The UK firm aims to cut waste in its factories around the world to 30kg for each 1kg of active pharmaceutical ingredient, compared with an average 100kg in 2005.

API is the active compound in medicines to treat or cure disease, from which the final pills or liquids are formulated and packaged for delivery to pharmacies and patients.

GSK vice president for environmental health and safety Jim Hagan told the FT: It was the idea of sustainability that drove the idea. You make an improvement to the environment and you achieve a reduction in costs.

The reductions come through messages including changing and reducing the number of chemical steps required, cutting the volume of solvents, and switching to continuous manufacture of a single drug to remove the wastage involved in stopping, changing and restarting batches of different products.

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.